家族性醛固酮增多症III型的新表型:醛固酮增多症与库欣综合征并存
报告首例家族性醛固酮增多症III型(FH-III)患者同时出现严重原发性醛固酮增多症(PA)与库欣综合征。患者为男性,2岁起严重高血压和低钾血症,20岁发生库欣综合征,检出KCNJ5胚系p.Glu145Gln杂合突变,双侧肾上腺大结节样增生,左侧肾上腺切除标本的原代细胞培养中维拉帕米和硝苯地平显著抑制醛固酮与皮质醇分泌。
要点
- 首例FH-III患者同时表现为严重PA与库欣综合征。
- 检出KCNJ5胚系p.Glu145Gln杂合突变。
- 肾上腺CYP11B2高表达,CYP11B1、CYP17A1和STAR mRNA表达相对低。
核心结论
- 首次报告同时患严重PA与库欣综合征的FH-III患者。
- 皮质醇分泌过多可能归因于增生的肾上腺体积过大,因其肾上腺CYP11B1表达相对低。
- 与醛固酮类似,突变肾上腺中皮质醇的合成与分泌可能由电压门控Ca2+通道介导。
研究设计与样本
- 病例报告:1例男性患者,2岁起严重高血压和低钾血症,20岁发生库欣综合征。
- 患者有双侧肾上腺大结节样增生,接受左侧肾上腺切除术。
- 对KCNJ5进行测序,并在体内和体外观察醛固酮与皮质醇的分泌。
主要发现
- 鉴定出KCNJ5胚系p.Glu145Gln杂合突变。
- 肾上腺中ARMC5、PRKAR1A、PDE8B、PDE11A和PRKACA基因及β-catenin、P53免疫活性正常。
- 与正常肾上腺皮质及其他肾上腺疾病相比,增生肾上腺中CYP11B2高表达,而CYP11B1、CYP17A1和STAR的mRNA表达相对低。
- 在切除的增生肾上腺原代细胞培养中,维拉帕米和硝苯地平显著抑制醛固酮与皮质醇的分泌以及CYP11B1、CYP11B2、CYP17A1和STAR的mRNA表达。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: To date, all the familial hyperaldosteronism type III (FH-III) patients reported presenting with typical primary aldosteronism (PA), without showing other adrenal hormone abnormalities. OBJECTIVE: This study characterized a novel phenotype of FH-III and explored the possible pathogenesis. PATIENTS AND METHODS: A male patient presented with severe hypertension and hypokalemia at the age of 2 years and developed Cushing's syndrome at 20 years. He was diagnosed with PA and Cushing's syndrome on the basis of typical biochemical findings. He had massive bilateral adrenal hyperplasia and underwent left adrenalectomy. KCNJ5 was sequenced, and secretion of aldosterone and cortisol were observed both in vivo and in vitro. RESULTS: A heterozygous germline p.Glu145Gln mutation of KCNJ5 was identified. ARMC5, PRKAR1A, PDE8B, PDE11A, and PRKACA genes and β-catenin, P53 immunoactivity were normal in the adrenal. CYP11B2 was highly expressed, whereas mRNA expression of CYP11B1, CYP17A1, and STAR was relatively low in the hyperplastic adrenal, compared with normal adrenal cortex and other adrenal diseases. In the primary cell culture of the resected hyperplastic adrenal, verapamil and nifedipine, two calcium channel blockers, markedly inhibited the secretion of both aldosterone and cortisol and the mRNA expression of CYP11B1, CYP11B2, CYP17A1, and STAR. CONCLUSIONS: We presented the first FH-III patient who had both severe PA and Cushing's syndrome. Hypersecretion of cortisol might be ascribed to overly large size of the hyperplastic adrenal because CYP11B1 expression was relatively low in his adrenal. Like aldosterone, synthesis and secretion of cortisol in the mutant adrenal may be mediated by voltage-gated Ca2+ channels.
引用
- Tong A, Liu G, Wang F, et al. A Novel Phenotype of Familial Hyperaldosteronism Type III: Concurrence of Aldosteronism and Cushing's Syndrome. J Clin Endocrinol Metab. 2016. PMID: 27403928
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。